Avidity Biosciences
RNAM
RNAM was delisted on the 26th of February, 2026.
115 hedge funds and large institutions have $757M invested in Avidity Biosciences in 2022 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 44 increasing their positions, 19 reducing their positions, and 5 closing their positions.
173,100% more call options, than puts
Call options by funds: $3.46M | Put options by funds: $2K
280% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 5
132% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 19
12% more funds holding
Funds holding: 103 → 115 (+12)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.12% less ownership
Funds ownership: 106.91% → 104.79% (-2.1%)
30% less capital invested
Capital invested by funds: $1.09B → $757M (-$328M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$33.7M |
| 2 |
BlackRock
New York
|
+$9.9M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$5.85M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.91M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$2.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWA
Aaron Wealth Advisors
Chicago,
Illinois
|
-$56.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.52M |
| 3 |
ACM
Altium Capital Management
New York
|
-$1.38M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$1M |
| 5 |
ACM
Alethea Capital Management
Mercer Island,
Washington
|
-$811K |
RNAM Hedge Fund Activity: Q2 2022 in Review
115 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q2 2022, worth a combined $757M — down 30% from $1.09B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new RNAM positions and 5 closed out — a net gain of 14 holders — while 44 added to existing stakes and 19 trimmed.
The largest buyer was Cowen and Company, opening a new position worth an estimated $33.7M. The largest seller was Aaron Wealth Advisors, cutting an estimated $56.1M.
- 115 institutional investors held Avidity Biosciences (RNAM) as of Q2 2022, up from 103 in Q1 2022.
- Funds reported $757M of Avidity Biosciences stock for Q2 2022, down 30% quarter-over-quarter.
- 19 funds opened new Avidity Biosciences positions in Q2 2022 and 5 closed out, a net change of +14 holders.
- The largest Avidity Biosciences buyer in Q2 2022 was Cowen and Company, an estimated $33.7M added.
- The largest Avidity Biosciences seller in Q2 2022 was Aaron Wealth Advisors, an estimated $56.1M sold.
Based on aggregated 13F filings for Q2 2022.